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ProfileHelping the Brain Heal ItselfA decade of research has yielded conclu-
sive evidence that the brain contains the
keys to its own repair. Once thought to be
born with all the neurons it would ever
have, the adult brain actually retains an
intrinsic source of neural regeneration
and repair. At least two populations of
stem cells, one in the hippocampus and
the other in the ventricles, are capable of
differentiating into neurons and integrating
into the brain’s elaborate synaptic network.
At least three startup companies are now
fielding treatments that that will direct this
natural healing system to ameliorate spe-
cificdiseases. The treatmentswill be tested
on humans for the first time within the year.
As a form of therapy, endogenous stem
cells offer a vast range of potential advan-
tages. Free of the ethical cloud shadowing
stem cell transplantation, endogenous stem
cell therapies offer a fast track to regulatory
approval. Noembryos, customcell cultures,
or other novel strategies are involved,
meaning that the Food and Drug Adminis-
tration is unlikely to require extraordinary
criteria to be met before approval.
But whether neural stem cell stimula-
tion has ripened to the point of commer-
cial viability remains to be seen. Introduc-
ing new compounds into the brain is
always risky; tinkering with natural pat-
terns of brain cell growth and differentia-
tion even more so. And basic questions
about the molecular pathways, cell mech-
anisms, and safety of these techniques
remain to be answered. Until these issues
have been resolved, skeptics say, re-
searchers have no business expanding
their studies to human subjects.
The effects of a stroke resemble a
bomb blast in the brain. Skills and memo-
ries vanish with the loss of every neuron.
In the weeks and months following injury,
brand new neurons will start to fill the void,
allowing many patients to regain some
of their lost skills. But healing in stroke
patients, most of whom are over 60, is
often incomplete at best. ‘‘The older you
get, the fewer endogenous stem cells you
have in your brain—and the more you need
them,’’ says Alan Moore, CEO of Stem Cell
Therapeutics.
The Calgary-based company wants to
hurry the healing process along with a hor-
mone called human chorionic gonadotro-240 Cell Stem Cell 3, September 11, 2008 ªpin, or HCG. Currently used for fertility
treatments, injections of the molecule
also induce proliferation of the brain’s
endogenous neural stem cells. HCG treat-
ment is followed by a course of the hor-
mone erythropoietin, or EPO. EPO is typ-
ically used to treat anemia and stimulates
the production of red blood cells; in the
brain, EPO encourages neural progeni-
tors to differentiate.
At present, the only treatments avail-
able for stroke are aspirin and tissue plas-
minogen activator, or tPA. tPA works well
at dissolving clots, but the drug must be
administered within 3 hours of a stroke
event. Meanwhile, the vast majority of
stroke patients don’t see a doctor until
after this window has slammed shut. By
contrast, says Moore, the HCG/EPO reg-
imen can be started up to 48 hr after
a stroke has occurred. ‘‘We let the dam-
age happen, which is mostly within the
first day. And we try to help fill the hole
back again and make you feel like you
haven’t had a stroke,’’ he says. Because
both compounds have already been
deemed safe for humans, the company
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trial of the regimen in Canada this year.
A double-blinded study with a placebo
control, the study will involve 134 pa-
tients. It will examine both protocol safety
and obtain preliminary measures of effi-
cacy based on improvement in NIH stroke
scale measurements of function. If the
drugs prove successful, says Moore, the
company will go on to test the regimen
in patients with traumatic brain injury.
Depression, too, is linked to altered
neurogenesis in the brain. For decades,
scientists have known that the volume of
the hippocampus tends to be smaller in
people with depression. Then in 2003,
Rene´ Hen of Columbia University found
that antidepressants don’t work on rats
lacking neural stem cells. The finding sug-
gested a more direct route to treat the
disorder: encouraging new nerve cells to
take root in the hippocampus.
BrainCells, Inc. of San Diego is employ-
ing this discovery to develop a new
generation of antidepressants. BrainCells
is screening libraries of bioactive com-
pounds for drugs that promote neurogen-
esis. Their hope is to be able to treat
patients who don’t respond to traditional
antidepressants, all of which produce
surges in the neurotransmitter serotonin.
The company’s ace in the hole, says chief
scientific officer Carrolee Barlow, is the
technology to culture stem cells in an en-
vironment that mimics conditions in the
brain (Figure 1). ‘‘We have a way to iden-
tify a completely new mechanism that
could promote neurogenesis in human
neural stem cells.and have a much bet-
ter chance of having efficacy in the clinic.’’
The company has identified at least
three compounds that appear to protect
differentiating stem cells that are already
in the process of becoming neurons. ‘‘Un-
der normal circumstances, a lot of neural
stem cells are born, but somewhere be-
tween 50 and 80 percent just die; they
never integrate,’’ says Barlow. ‘‘You may
not have to do anything to increase the
number of neural stem cells if you can
help them differentiate and survive.’’ The
company’s leading compound, called BCI-
540, has already been through ex-
tensive human safety tests in trials for a
nonpsychiatric application. Formulated
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clinical trials in 90 patients. The study will
examine whether the treatment reduces
levels of depression and anxiety as mea-
sured with a standard battery of questions
used for psychiatric diagnosis. Results are
expected in mid-2009.
If stem cells offer the ability to replenish
much-needed neurons, then stem cell
proliferation might be just what’s needed
to reverse the effects of neurodegenera-
tive disorders. Scientists at NeuroNova
of Stockholm, Sweden, are attempting
to harness neural stem cells to treat Par-
kinson’s disease. Over time, the disease
destroys dopamine-producing neurons
in the substantia nigra of the brain. The
cell loss leads to tremors and a progres-
sive loss of motor function. NeuroNova
aims to restore these dopaminergic neu-
rons with the help of platelet-derived
growth factor BB, or PDGF-BB. Best
known for promoting angiogenesis, PDGF
also causes proliferation in many other
cell types, including glial and neural pro-
genitor cells. NeuroNova plans to deliver
the drug via a catheter implanted into
the brain’s intraventricular space. There,
says NeuroNova’s chief scientific officer
Anders Haegerstrand, PDGF triggers
neuronal stem cells to proliferate and
interact with local dopamine fibers. In
monkeys and rats, the treatment provides
long-lasting improvements in motor skills
as well as a marked increase in dopa-
mine-producing neurons in the substantia
nigra.
Promising as they might sound, the sci-
ence behind all three approaches remains
decidedly vague. The cell populations af-fected have not been fully characterized,
and the mechanisms of interaction haven’t
yet been worked out. Part of the problem
lies in the difficulty of tracking neural
stem cells as they mature and differenti-
ate. The act of labeling neural stem cells
with a synthetic nucleotide often kills
them. And the gold standard for confirm-
ing neurogenesis in the brain—a tissue
biopsy—is out of the question for human
subjects. These limitations have forced
scientists like NeuroNova’s Haegerstrand
to rely on other criteria to evaluate their
therapies. ‘‘We don’t claim that our prolif-
erating cells are maturing into full dopami-
nergic cells. This might be the case; we
just can’t trace them long enough to tell.’’
That’s too many unknowns to justify
human subject testing, says Dr. Stephen
Goldman of the University of Rochester
Medical Center. As a practicing neurolo-
gist, Goldman is painfully attuned to the
potential downsides of these therapies.
‘‘I see patients, and have to worry about
off-target and side effects of treatment
strategies,’’ he says.
Though Goldman studies endogenous
stem cells himself, he views clinical trials
at this date as somewhere between irre-
sponsible and dangerous. Introducing mi-
togens to the brain has the potential to
trigger runaway growth in many brain re-
gions and cell types. ‘‘There are all sorts
of ways to nonspecifically stimulate stem
cells. But these don’t necessarily give
you control over what populations are be-
ing mobilized,’’ Goldman says. If the stim-
ulated cells mature into glial cells instead
of neurons, they have the potential to
form a scar or even sow the seeds ofCell Stem Cell 3, Sa brain tumor. Other side effects could in-
clude imbalances in neurotransmitters
that might make someone with depres-
sion more suicidal. ‘‘The devil here is in
the details—the drugs, the cell popula-
tions, and the disease.’’
The companies, for their part, say they
are well aware of the dangers, and they in-
clude respected scientists in their organi-
zations to help minimize those risks. Both
Rene´ Hen and Fred Gage of the Salk Insti-
tute, who first discovered neurogenesis in
the adult brain, are on the scientific advi-
sory board of BrainCells Inc. Meanwhile,
Samuel Weiss of the University of Cal-
gary, Canada, serves as the research
arm of Stem Cell Therapeutics; the com-
pany’s projects and technologies are all
based on his work and patents. And all
three companies are taking steps to en-
sure their subjects’ safety. NeuroNova,
for example, will require potential patients
to undergo CT scans prior to therapy to
avoid the risk of feeding any small existing
tumors. Stem Cell Therapeutics claims
that EPO shuts off stem cell proliferation,
giving the regimen some built-in protec-
tion against brain cancer. Meanwhile,
BrainCells plans to keep a sharp eye
peeled for tumors, scarring, and any dif-
ferences in neurogenic profile between
its drugs and existing antidepressants.
Parkinson’s and other patients shouldn’t
have to wait for science to develop an
entirely new suite of cellular analyses
and tests, argues Ulf Ljungberg, Neuro-
Nova’s president and CEO. As for
whether stem cell stimulation strategies
will work in the clinic, he says, ‘‘there’s
no other way of knowing than trying.’’
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